301-04-009 ISMRM Abstract

Metabolic Assessment of Fatty Liver Disease in Humans Using Hyperpolarized [1-¹³C]Pyruvate MRI

Primary: Body - Liver

Secondary: Contrast Mechanisms - Hyperpolarized MR (Non-Gas)

301-04-009 · Innovations in Contrast Mechanisms for MRI · Monday, 11 May, 4:10 PM–6:00 PM · Hall 1A

Keywords: 1-13C Pyruvate Hyperpolarized 13C MRI Fatty liver disease Metabolic Dysfunction-Associated Steatohepatitis

Accepted

Yaewon Kim¹, Hsin-Yu Chen¹, Jeremy W Gordon¹, Aras Mattis², Jacquelyn Maher³, Bilal Hameed³, Robert Bok¹, Dan Vigneron^1,4, Cornelius von Morze⁵, Michael Ohliger ¹

¹Department of Radiology and Biomedical Imaging, University Of California, San Francisco (UCSF), United States of America

²Department of Pathology, University Of California, San Francisco (UCSF), United States of America

³Department of Medicine, University Of California, San Francisco (UCSF), United States of America

⁴Department of Neurological Surgery, University Of California, San Francisco (UCSF), United States of America

⁵Department of Radiology, Washington University School of Medicine, St. Louis, United States of America

Presenting Author: Michael Ohliger

Synopsis

Motivation:

Goals:

Approach:

Results:

Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

References

1. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335-1347. doi:10.1097/HEP.0000000000000004 [doi]

2. Wong VWS, Ekstedt M, Wong GLH, Hagström H. Changing epidemiology, global trends and implications for outcomes of NAFLD. Journal of Hepatology. 2023;79(3):842-852. doi:10.1016/j.jhep.2023.04.036 [doi]

3. Wang ZJ, Ohliger MA, Larson PEZ, et al. Hyperpolarized 13C MRI: State of the Art and Future Directions. Radiology. 2019;291(2):273-284. doi:10.1148/radiol.2019182391 [doi]

4. Moon CM, Oh CH, Ahn KY, et al. Metabolic biomarkers for non-alcoholic fatty liver disease induced by high-fat diet: In vivo magnetic resonance spectroscopy of hyperpolarized [1-13C] pyruvate. Biochemical and Biophysical Research Communications. 2017;482(1):112-119. doi:10.1016/j.bbrc.2016.08.118 [doi]

5. Piraquive Agudelo J, Kim Y, Agarwal S, et al. Hyperpolarized [1‐13C] pyruvate MRSI to detect metabolic changes in liver in a methionine and choline‐deficient diet rat model of fatty liver disease. Magnetic Resonance in Med. 2024;91(4):1625-1636. doi:10.1002/mrm.29954 [doi]

6. Lee PM, Chen H, Gordon JW, et al. WHOLE‐ABDOMEN Metabolic Imaging of Healthy Volunteers Using Hyperpolarized [1‐13C]pyruvate MRI. Magnetic Resonance Imaging. April 2022:jmri.28196. doi:10.1002/jmri.28196 [doi]

7. Nickles TM, Kim Y, Lee PM, et al. Hyperpolarized 13C metabolic imaging of the human abdomen with spatiotemporal denoising. Magnetic Resonance in Med. 2024;91(5):2153-2161. doi:10.1002/mrm.29985 [doi]

8. Larson PEZ, Chen HY, Gordon JW, et al. Investigation of analysis methods for hyperpolarized 13C-pyruvate metabolic MRI in prostate cancer patients: Hyperpolarized Pyruvate Prostate Cancer Analysis Methods. NMR in Biomedicine. 2018;31(11):e3997. doi:10.1002/nbm.3997 [doi]

9. Kim Y, Nickles TM, Lee PM, et al. A data‐driven approach for improved quantification of in vivo metabolic conversion rates of hyperpolarized [1‐13C]pyruvate. Magnetic Resonance in Med. 2025;93(6):2346-2356. doi:10.1002/mrm.30445 [doi]

10. Josan S, Billingsley K, Orduna J, et al. Assessing inflammatory liver injury in an acute CCl4 model using dynamic 3D metabolic imaging of hyperpolarized [1‐13C]pyruvate. NMR in Biomedicine. 2015;28(12):1671-1677. doi:10.1002/nbm.3431 [doi]

11. Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2019;16(6):377-386. doi:10.1038/s41575-019-0144-8 [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/301-04-009